LongevityNot approvedEvidence tier: Animal Only

Humanin-G (HNG)

Last updated October 21, 2026. Approval line checked October 21, 2026. No compounding source date is assigned.

FDA status

Not approved

Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.

FDA: Unapproved drugs

Evidence tier

Animal Only. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 2/5. 145 PubMed citations indexed.

Humanin-G (HNG) in the literature

Glycine-substituted Humanin analog with ~1000x greater potency; activates gp130/CNTFR/WSX-1 receptor complex triggering STAT3 and PI3K/Akt neuroprotective cascades.

What the literature studies

Neuroprotection & Metabolic Protection

Evidence tier

Animal Only

Compounding record

Status not verified

Confidence
2/5

Regulatory record

Status not verified. No product-specific FDA primary source is recorded for this entry. FDA approval and compounding eligibility are not verified. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.

Regulatory source not verified; no checked date is assigned.

No human trials; all data from animal and cell models; pharmacokinetics and human safety profile unknown.

Questions

Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.